DSTC, a Japanese preclinical CRO known for its ion channel assay capabilities, and European Life science tech company InSilicoTrials, entered a partnership to provide the Japanese pharmaceutical industry with access to innovative services that leverage cutting-edge technology such as modeling and simulation.
 
DSTC and InSilicoTrials will combine their expertise to advance innovation and digitalization, following the recommendations of regulatory bodies, including the FDA, EMA and PMDA, in an effort to cut the cost and time-to-market of drug development, while increasing the safety of new medicines and reduce animal and human testing.
 
DSTC is a pioneer of hERG assay in Japan and is the only CRO in Japan providing services that can thoroughly mimic CiPA protocols. Safety assessment studies include general toxicology, specific toxicology, genetic toxicology, safety pharmacology, and study methods alternative to the animal use.
 
InSilicoTrials is the first cloud-based platform that provides tools to perform computational modeling and simulation in drug development. Simulation is a key factor to reduce in vitro and in vivo test costs and shorten time-to-market of new medicines.
 
The partnership will bring a very complex and expensive technology like modeling and simulation to the Japanese life science market in a cost-effective and reliable way, with the objective of accelerating innovation and the uptake of in silico methods in drug development, to benefit patients.
 
“We are thrilled to this opportunity between DSTC and InSilicoTrials. In Japan, the in silico services are still at the dawning stage, but we are confident that by partnering with InSilicoTrials, a company with an excellent track record and experiences in the EU and the U.S., our clients will be able to share their global knowledge and experience success in the future of digitalization”, says Hirohito Takahashi, CEO of DSTC. “Putting together InSilicoTrials’ expertise in modeling and simulation and ours in ion channel assay capabilities shall bring tremendous benefits to our shared customers.”
 
“We are very excited at the opportunity of bringing in silico methods to the Japanese life science industry with a leader such as DSTC”, says Luca Emili, CEO and Fouder of InSilicoTrials. “Our partner has a reputation for offering the best and most reliable drug safety tests in Japan and we can help them increase reliability and safety by adding in silico methods to the standard practice, as encouraged by all regulatory agencies around the world. This will mean being able to better satisfy customers thanks to innovation.”